Antiviral therapy for hepatitis b

Details Antiviral therapy for hepatitis b Antiviral therapy for hepatitis b

A - Human Necessities

61

K

167/202

A61K 31/70 (2006.01) A61K 31/52 (2006.01) C07D 473/16 (2006.01) C07D 473/18 (2006.01) C07D 473/24 (2006.01) C07D 473/30 (2006.01) C07D 473/32 (2006.01) C07D 473/34 (2006.01) C07D 473/40 (2006.01)

Patent

CA 1327000

21 ABSTRACT OF THE DISCLOSURE A method is disclosed for the treatment of hepadnavirus infection in animals. Animals infected with duck hepatitis B virus may be treated with the 2',3'-dideoxynucleoside of adenine, guanine, hypoxanthine, 2,6-diaminopurine or various analogs of substituted purines. Several purine 2',3'- dideoxynucleosides inhibit duck hepatitis B virus in hepatocyte culture >99% at 1 µg/ml. Potent in vivo efficacy of the 2,6-diaminopurine 2',3'- dideoxynucleoside for clearance of duck hepatitis B virus from the sera of Pekin ducks is demonstrated. The selective effect on hepadnavirus replication by the purine 2',3'-dideoxynucleosides is based on the discovery of an unexpected sensitivity of hepadnavirus to purine 2',3'-dideoxynucleoside analogs. These compounds present a new antiviral therapy of acute or persistent hepadnavirus infections.

573873

Affiliated with

Also associated with

Rating

Antiviral therapy for hepatitis b does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antiviral therapy for hepatitis b, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiviral therapy for hepatitis b will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1292548